Breast Cancer Trial, Recruiting NCT05876065 Sponsor: Wenjin Yin Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05876065
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 years or older
  • People with a general health status rated as ECOG 2 or below (a scale used to measure how much a person's cancer affects their daily activities — confirm with trial site if unsure what this means for a specific situation)
  • People who have been diagnosed with primary breast cancer confirmed by laboratory testing, and whose cancer has come back or spread to other parts of the body, confirmed by laboratory or imaging tests
  • People whose breast cancer falls into one of these categories based on tumour markers: HR+/HER2+, HR-/HER2+, or HR-/HER2- (these refer to specific proteins found on cancer cells — the trial site can explain which category applies)
  • People who have at least one measurable area of cancer, or cancer that has spread only to bones (in a dissolving or mixed pattern), as assessed by standard imaging guidelines
  • People whose cancer responded to or stabilised with previous treatment (meaning the cancer showed complete response, partial response, or stable disease)
  • People with an expected survival of at least 6 months
  • People with adequate organ function (meaning the liver, kidneys, and other organs are working well enough — the trial site will assess this)

Who may not be able to join:

  • People who are currently pregnant or breastfeeding
  • People whose cancer has spread to the central nervous system (the brain or spinal cord)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wenjin Yin, M.D., Renji Hospital,School of Medicine, Shanghai Jiaotong University

Phone: 86(21)68385569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Wenjin Yin
Registry
ClinicalTrials.gov
Start date
1 June 2023
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov